Please ensure Javascript is enabled for purposes of website accessibility
Search
▲ S&P 500 + | ▲ Stock Advisor + Join The Motley Fool
Accessibility Log In Help
Accessibility Menu
The Motley Fool
Our Services
Premium Services
Stock Advisor
Our Flagship Service
Return
S&P Return
Rule Breakers
High-growth Stocks
Return
S&P Return
Returns as of
View Our Services
Investing 101
  • How to Invest Money
  • What to Invest In
  • How to Invest in Stocks
  • How to Invest in Index Funds
  • How to Invest in ETFs
  • How to Invest in Real Estate
Best Accounts
  • Best Stock Brokers
  • Best Brokers for Beginners
  • Best IRA Accounts
  • Best Roth IRA Accounts
  • Best Options Brokers
  • Best Crypto Apps
Stock Market Basics
  • Stock Market 101
  • Types of Stocks
  • Stock Market Sectors
  • Stock Market Indexes
  • S&P 500
  • Dow Jones
  • Nasdaq Composite
Premium Services
Stock Advisor
Our Flagship Service
Return
S&P Return
Rule Breakers
High-growth Stocks
Return
S&P Return
Returns as of
View Our Services
Stocks
  • Growth Stocks
  • Value Stocks
  • Dividend Stocks
  • Small Cap Stocks
  • Large Cap Stocks
  • Blue Chip Stocks
Industries to Invest In
  • Consumer Goods
  • Technology
  • Energy
  • Healthcare
  • Financial
  • Cryptocurrency
  • NFTs
News
  • Top Stocks to Buy in 2022
  • Stock Market News
Getting Started
  • Retirement 101
  • Why to Start Saving Now
  • Types of Retirement Accounts
  • 401k Basics
  • IRA Basics
  • HSA Basics
Planning for Retirement
  • How Much Do I Need to Retire?
  • When To Retire
  • Factoring in Social Security
  • What is the Full Retirement Age?
  • Investing for Retirement
  • Retirement Strategies
Retired: What Now?
  • Retiring in 2022
  • Withdrawal Strategies
  • Healthcare in Retirement
  • Taxes in Retirement
  • Estate Planning
Credit Cards
  • Best Credit Cards
  • Best Cash Back Cards
  • Best Balance Transfer Cards
  • Best Travel Credit Cards
  • Best 0% Credit Cards
  • Best Rewards Cards
  • Best Cards for Bad Credit
Bank & Loans
  • Best Savings Accounts
  • Best Checking Accounts
  • Best CD Rates
  • Best Personal Loans
  • Best Debt Consolidation Loans
Homebuying
  • Best Mortgage Lenders
  • Best Mortgage Refi Lenders
  • Best Lenders for First-time Buyers
  • Best FHA Mortgage Lenders
  • Current Mortgage Rates
Guides
  • Credit Cards 101
  • Bank Accounts 101
  • Home Loans 101
  • Pay Off Debt
  • Increase Your Credit Score
Our Purpose:
To make the world smarter, happier, and richer.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Who Is the Motley Fool?
  • About Us
  • Investing Philosophy
  • Reviews
  • The Motley Fool Foundation
  • Media Inquiries
  • Contact Us
Fool Podcasts
  • Podcasts Home
  • Motley Fool Money
  • Rule Breaker Investing
Social Media +
  • Facebook
  • Twitter
  • YouTube
  • Discussion Boards
  • CAPS - Stock Picking Community
Other Services
  • The Ascent
Top 10 Stocks
Search
  • Our Services
    • Investing 101
      • How to Invest Money
      • What to Invest In
      • How to Invest in Stocks
      • How to Invest in Index Funds
      • How to Invest in ETFs
      • How to Invest in Real Estate
      Best Accounts
      • Best Stock Brokers
      • Best Brokers for Beginners
      • Best IRA Accounts
      • Best Roth IRA Accounts
      • Best Options Brokers
      • Best Crypto Apps
      Stock Market Basics
      • Stock Market 101
      • Types of Stocks
      • Stock Market Sectors
      • Stock Market Indexes
      • S&P 500
      • Dow Jones
      • Nasdaq Composite
      Premium Services
      Stock Advisor
      Our Flagship Service
      Return
      S&P Return
      Rule Breakers
      High-growth Stocks
      Return
      S&P Return
      Returns as of
      View Our Services
    • Stocks
      • Growth Stocks
      • Value Stocks
      • Dividend Stocks
      • Small Cap Stocks
      • Large Cap Stocks
      • Blue Chip Stocks
      Industries to Invest In
      • Consumer Goods
      • Technology
      • Energy
      • Healthcare
      • Financial
      • Cryptocurrency
      • NFTs
      News
      • Top Stocks to Buy in 2022
      • Stock Market News
      Premium Services
      Stock Advisor
      Our Flagship Service
      Return
      S&P Return
      Rule Breakers
      High-growth Stocks
      Return
      S&P Return
      Returns as of
      View Our Services
    • Getting Started
      • Retirement 101
      • Why to Start Saving Now
      • Types of Retirement Accounts
      • 401k Basics
      • IRA Basics
      • HSA Basics
      Planning for Retirement
      • How Much Do I Need to Retire?
      • When To Retire
      • Factoring in Social Security
      • What is the Full Retirement Age?
      • Investing for Retirement
      • Retirement Strategies
      Retired: What Now?
      • Retiring in 2022
      • Withdrawal Strategies
      • Healthcare in Retirement
      • Taxes in Retirement
      • Estate Planning
    • Credit Cards
      • Best Credit Cards
      • Best Cash Back Cards
      • Best Balance Transfer Cards
      • Best Travel Credit Cards
      • Best 0% Credit Cards
      • Best Rewards Cards
      • Best Cards for Bad Credit
      Bank & Loans
      • Best Savings Accounts
      • Best Checking Accounts
      • Best CD Rates
      • Best Personal Loans
      • Best Debt Consolidation Loans
      Homebuying
      • Best Mortgage Lenders
      • Best Mortgage Refi Lenders
      • Best Lenders for First-time Buyers
      • Best FHA Mortgage Lenders
      • Current Mortgage Rates
      Guides
      • Credit Cards 101
      • Bank Accounts 101
      • Home Loans 101
      • Pay Off Debt
      • Increase Your Credit Score
    • Who Is the Motley Fool?
      • About Us
      • Investing Philosophy
      • Reviews
      • The Motley Fool Foundation
      • Media Inquiries
      • Contact Us
      Fool Podcasts
      • Podcasts Home
      • Motley Fool Money
      • Rule Breaker Investing
      Social Media +
      • Facebook
      • Twitter
      • YouTube
      • Discussion Boards
      • CAPS - Stock Picking Community
      Other Services
      • The Ascent
      Our Purpose:
      To make the world smarter, happier, and richer.

      Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

  • Log In
  • Help
  • Join The Motley Fool
Top 10 Stocks

Regeneron Pharmaceuticals (NASDAQ: REGN)

$635.08
Arrow-Thin-Down
(-0.4%)
-$2.28
Price as of March 31, 2025, 3:58 p.m. ET
Jump to:
OverviewReturn vs. S&PCompany InfoNews & AnalysisFinancial HealthValuationPodcast EpisodesRelated Stocks
  • Overview
  • Return vs. S&P
  • Company Info
  • News & Analysis
  • Financial Health
  • Valuation
  • Podcast Episodes
  • Related Stocks

Key Data Points

Current Price
The most recent price per share for this stock.
$635.08
Daily Change
The percentage change for this company's share price today.
(-0.4%) -$2.28
Day's Range
The range between the highest and lowest prices at which this company's shares traded today.
$619.31 - $640.60
Previous Close
The final price at which this company's shares traded during the previous trading day.
$634.23
Open
The starting price at which this company's shares traded during the current trading day.
$630.08
Beta
Beta measures a stock or portfolio's movement relative to the overall market, or to a specific stock index. A stock with a beta of 1 is theoretically as volatile as the overall market. A beta of more than 1 indicates a stock is more volatile than the market, and a beta of less than one indicates it is less volatile. For example, a beta of 2 implies that a stock will move twice as much as the market, whereas a beta of .5 implies half the movement of the market.
0.56
Volume
The number of shares of this company's stock that have traded today.
1,066,328
Average Volume
The average number of shares that are traded over a trailing three-months period.
942,866
Sector
An industry or industry subset that a company operates within. There are 11 different stock market sectors, according to the Global Industry Classification Standard (GICS), the most commonly used classification system.
Health Care
Market Cap
The market value of a company, in total dollars, also called "market capitalization." Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding.
$69B
Market Cap / Employee
The market cap of a company divided by the total number of the company's employees.
$5M
52wk Range
The range between the highest and lowest prices at which this company's shares traded over the past year.
$618.51 - $1,211.20
Revenue
The total sales generated by a company during the most recent year. Also referred to as "the top line" of the income statement.
$14B
Gross Margin
The gross profit expressed as a percentage of total revenue. Higher is usually better.
82.73%
Dividend Yield
The percentage of a company's share price that it pays in dividends each year.
N/A
EPS
Earnings per share (EPS) indicates how profitable a company is on a per-share basis. EPS is calculated by subtracting any preferred dividends from a company's net income and dividing that amount by the number of shares outstanding.
$38.29
CAPs Rating
The percentage of Motley Fool CAPS user ratings that predict this company will outperform the market. Based on sentiment data from The Motley Fool's CAPS community.
-
Industry
A group of companies that engage in the same primary business activity.
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Regeneron Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
REGN -33.69% +41.97% +7.25% +2,921%
S&P +6.22% +119.59% +17.02% +1,379%

Regeneron Pharmaceuticals Company Info

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

News & Analysis

The Fool has written over 300 articles on Regeneron Pharmaceuticals.
Featured Article

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Prosper Junior Bakiny  |  Mar 7, 2025
Featured Article

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Prosper Junior Bakiny  |  Feb 17, 2025

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

Eric Volkman  |  Feb 4, 2025

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street

Prosper Junior Bakiny  |  Dec 31, 2024

Should You Buy the Dip on This Top Growth Stock?

Prosper Junior Bakiny  |  Oct 2, 2024

The biotech needs to overcome an issue most drugmakers face at some point.

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

Prosper Junior Bakiny  |  Sep 4, 2024

These stocks have generally delivered competitive returns.

Is Regeneron Pharmaceuticals Due for a Stock Split?

David Jagielski  |  Aug 3, 2024

Would a stock split help lead Regeneron Pharmaceuticals shares higher?

Should You Sell This Stock Following a Regulatory Roadblock?

Prosper Junior Bakiny  |  Apr 5, 2024

It's not the first such obstacle this high-performing drugmaker has faced.

Financial Health

General

Q4 2024 YoY Change
Revenue
The total sales generated by a company during the most recent year. Also referred to as "the top line" of the income statement.
$3.79B +10.3%
Gross Profit
Gross profit is how much money a company makes after subtracting the cost of goods sold (COGS) from revenue, or total sales. It gives a view into profitability per unit produced for that company, before removing fixed costs like salaries or rent.
$3.10B +10.4%
Gross Margin
The gross profit expressed as a percentage of total revenue. Higher is usually better.
81.8% +0.1%
Market Cap
The market value of a company, in total dollars, also called "market capitalization." Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding.
$78.28B -18.2%
Market Cap / Employee
The market cap of a company divided by the total number of the company's employees.
$5.18M-
Employees
How many employees work for this company, as of our most recent data.
15,106 -
Net Income
The amount of accounting earnings (not cash earnings) left after all expenses have been subtracted from total revenue. Called the "bottom line" because it is shown at the bottom of the income statement.
$917.70M -20.9%
EBITDA
Earnings before interest, taxes, depreciation, and amortization. An easy way to calculate one measure of a company's cash flow. It is sometimes criticized for not being a proper, or complete, measure of cash flow.
$1.15B -0.9%

Revenue Growth Rate

Earnings Per Share Growth Rate

Assets

Q4 2024 YoY Change
Net Cash
Total cash and short-term investments (that can quickly be turned into cash) minus total debt. If it's positive, the company has more cash than debt, and vice versa if it is negative. Don't assume that a negative value is bad, as it depends on the industry.
$2.49B -8.9%
Accounts Receivable
Cash the company has not yet received from selling its product (i.e., unpaid invoices). This generally grows with revenue, though you should investigate if this growth rate differs markedly from the company's revenue growth rate.
$6.21B +9.6%
Inventory
The amount of goods held for sale or in the process of being manufactured. These include finished goods (ready to be sold), in progress (still being made), and raw materials (not yet started making). Changes in inventory tie into cost of goods sold (COGS), the expense subtracted from revenue to calculate gross profit.
3,087.30 +19.6%

Liabilities

Q4 2024 YoY Change
Long Term Debt
Debt that has to be paid back more than a year from the balance sheet date. This is often bonds issued by the company. Sometimes leases are included as debt, depending on the analysis.
$2.91B +7.6%
Short Term Debt
Debt that has to be paid back within the next year. This inludes things like short-term bank loans and bonds due this year.
$30.30M-

Ratios

Q4 2024 YoY Change
Return On Assets
Net income divided by total assets. This is usually used for asset-heavy companies (like industrials or manufacturers). Return on assets shows how efficiently a company uses its assets to generate earnings. Higher is usually better, but ranges depend on the industry.
12.4% -1.9%
Return On Invested Capital
Net operating profit after taxes (NOPAT) divided by average invested capital. A measure of capital allocation efficiency, the return on invested capital (ROIC) shows what return a company earns on money it invests.
22.7% -9.6%

Cash Flow

Q4 2024 YoY Change
Free Cash Flow
Free Cash Flow (FCF) shows how much money a company has remaining after paying for operating expenses and capital expenditures. Calculated by subtracting capital expenditures from cash flow from operations.
$1.06B +26.8%
Operating Free Cash Flow
The cash generated by a company's core business operations, before capital expenditures have been removed.
$1.26B +15.9%

Valuation

Q1 2024 Q2 2024 Q3 2024 Q4 2024 YoY Change
Price to Earnings
The price-to-earnings (P/E) ratio is derived by taking the price per share of stock and dividing it by the earnings per share for the most recent trailing 12 months (TTM). This value can then be compared to other P/Es, whether of an index, industry, or an individual company.
28.43 27.83 26.01 18.61 -26.4%
Price to Book
This is derived by dividing a company's stock price by its total stockholders' equity (or book value). It shows the value of a company's market capitalization relative to its book value.
4.05 4.29 4.11 2.67 -30.3%
Price to Sales
Market cap divided by total sales for the past four quarters. This can be used if a company is not yet generating profits.
8.46 8.99 8.82 5.71 -25.1%
Price to Tangible Book Value
This is derived by dividing a company's stock price by its total stockholders' equity minus intangible asstes. Price to tangible book value shows the value of a company relative to its hard or tangible assets.
4.22 4.47 4.27 2.78 -30.5%
Price to Free Cash Flow TTM
Price to free cash flow (FCF) shows the market capitalization of a company relative to how much free cash flow it generated over the preceding 12 months.
27.26 36.44 35.51 22.12 -14.2%
Enterprise Value to EBITDA
EV to EBITDA shows the enterprise value (market cap plus debt minus cash) of a company compared to the earnings before interest, taxes, depreciation, and amortization.
118 94.03 84.77 65.04 -17.6%
Free Cash Flow Yield
Free cash flow divided by market capitalization.
3.7% 2.7% 2.8% 4.5% +16.6%
Return on Equity
Return on equity (ROE) measures a company's financial performance calculated by dividing net income by total shareholders' equity. This shows how efficiently a company is generating profits, with higher being better.
15.3% 16.6% 17.2% 16.0% -1.9%
Total Debt
All debt owed by the company, including both long-term and short-term debt. This does not include accounts payable and similar liabilities, but may include leases depending on the analysis.
$2.70B$2.70B$2.70B$2.94B +8.7%

Podcast Episodes

cover_MF

Regeneron Stock Up on COVID-19 Breakthrough

Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.

Mac Greer  |  Mar 19, 2020
20181212_IF_Healthcare_thumb_02

Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018

Key trials suggest doctors may change how they treat patients with cardiovascular disease.

Motley Fool Staff  |  Dec 17, 2018

Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

Todd Campbell  |  Aug 17, 2017

Related Stocks

NASDAQ: VRTX

Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Quote
Market Cap
$124B
Current Price
$484.82

NASDAQ: ILMN

Illumina

Illumina Stock Quote
Market Cap
$13B
Current Price
$79.34

NYSE: BMY

Bristol Myers Squibb

Bristol Myers Squibb Stock Quote
Market Cap
$124B
Current Price
$60.99

NASDAQ: EXEL

Exelixis

Exelixis Stock Quote
Market Cap
$10B
Current Price
$36.92

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services
The Motley Fool

Making the world smarter, happier, and richer.

  • Facebook Facebook
  • Twitter Twitter
  • Linked In LinkedIn
  • Pinterest Pinterest
  • YouTube YouTube
  • Instagram Instagram
  • Tiktok TikTok

© 1995 - 2025 The Motley Fool. All rights reserved.

Market data powered by Xignite and Polygon.io.

About The Motley Fool

  • About Us
  • Careers
  • Research
  • Newsroom
  • Contact
  • Advertise

Our Services

  • Stock Advisor
  • Epic
  • Epic Plus
  • Fool Portfolios
  • Fool One
  • Motley Fool Money

Around the Globe

  • Fool UK
  • Fool Australia
  • Fool Canada

Free Tools

  • CAPS Stock Ratings
  • Discussion Boards
  • Calculators
  • Financial Dictionary

Affiliates & Friends

  • Motley Fool Asset Management
  • Motley Fool Wealth Management
  • Motley Fool Ventures
  • Motley Fool Foundation
  • Become an Affiliate Partner
  • Terms of Use
  • Privacy Policy
  • Disclosure Policy
  • Accessibility Policy
  • Copyright, Trademark and Patent Information
  • Terms and Conditions
  • Do Not Sell My Personal Information
Current